Jacob C Reijneveld

Learn More
We read Litofsky and Resnick's timely and useful review of depression in brain tumour patients with interest [1]. The authors identified screening for depression as an issue requiring future study. Because screening is often targeted at high-risk groups, it is important to study the risk factors for depression in brain tumour patients. The authors state(More)
PURPOSE OF REVIEW Brain tumor patients suffer from cognitive deficits, regardless of tumor grade or location. Deficits have a general character, falling in the domains of attention, working memory, information processing speed, and executive functioning. This review explores a new, brain network-based view of these deficits in brain tumor patients. RECENT(More)
Depression is one of the leading causes of global disability, and a considerable hidden morbidity among patients with glioma. In this narrative review, we summarise what is currently known about depression in glioma, the main unanswered questions and the types of studies that should be prioritised in order to find out. We conclude by calling for a(More)
Health-related quality of life (HRQOL) is a multidimensional concept used to measure patients' functioning and well-being. In recent decades, HRQOL has become an important (secondary) outcome measure in clinical trials for brain tumor patients. It could be questioned, however, whether HRQOL is the only useful outcome measure for assessing the level of(More)
  • 1